Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154281 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
A Phase 1 study, sponsored by Avera McKennan Hospital & University Health Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03154281 is a Phase 1 study that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 14 participants.
The verdict
NCT03154281, a Phase 1 study, has completed, sponsored by Avera McKennan Hospital & University Health Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.
Interventions
- DRUG everolimus
- DRUG niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154281
The ClinicalTrials.gov registry entry for NCT03154281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which everolimus is the first listed.
NCT03154281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154281 about?
NCT03154281 is a clinical study titled "Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast". Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.
What is the current status of trial NCT03154281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-07-26. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT03154281?
The interventions under investigation include: everolimus (DRUG), niraparib (DRUG).
Who is sponsoring clinical trial NCT03154281?
This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.